Free Newsletter
Cancer cells much more likely to mutate
Once cells become cancerous they are 100 times more likely to genetically mutate than normal cells, according to researchers. And that conclusion could spell serious trouble for research programs that seek to control a single gene involved in malignancy. "This is very bad news, because it means that cancer cells in a tumor will have mutations that protect them from therapeutics," said lead investigator Lawrence Loeb of the University of Washington School of Medicine. The research also points to a new method to gauge the malignancy of a tumor by evaluating the number of mutations it has.
- check out the release
- read the report on the cancer study from News-Medical
Related Articles:
Cancer-killing viruses head to the clinic. Report
"Scrap" DNA can turn off tumor cell division. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: